earnings
confidence high
sentiment neutral
materiality 0.60
89bio Q2 2025 net loss $111.5M; cash $561.2M; MASH Phase 3 data expected 1H 2027
89bio, Inc.
2025-Q2 EPS reported
-$1.20
- Net loss of $111.5M vs $48.0M in Q2 2024, driven by higher R&D expenses including $42.4M facility payment.
- Cash, cash equivalents, and marketable securities total $561.2M as of June 30, 2025.
- Phase 3 ENLIGHTEN-Fibrosis topline histology data expected 1H 2027; ENLIGHTEN-Cirrhosis data in 2028.
- Phase 3 ENTRUST topline data in severe hypertriglyceridemia expected Q1 2026.
- Remaining facility obligation of $13.5M milestone payment due in 2026.
item 2.02item 9.01